Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IRADIMED CORP Director's Dealing 2021

Nov 10, 2021

32324_dirs_2021-11-10_d001e3b9-5dff-4c07-9974-9d1b7d6a4d11.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2021-11-05

Reporting Person: HAWKINS JAMES B (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-05 Common Stock A 5501 $1.48 Acquired 22769 Direct
2021-11-05 Common Stock S 5501 $38.25 Disposed 17268 Direct
2021-11-08 Common Stock A 9479 $1.48 Acquired 26747 Direct
2021-11-08 Common Stock S 9479 $38.9809 Disposed 17268 Direct
2021-11-09 Common Stock A 1234 $1.48 Acquired 18502 Direct
2021-11-09 Common Stock S 1234 $37.7501 Disposed 17268 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-11-05 Stock Options (Right to Buy) $1.48 M 5501 Disposed 2023-12-31 Common Stock (5501) Direct
2021-11-08 Stock Options (Right to Buy) $1.48 M 9479 Disposed 2023-12-31 Common Stock (9479) Direct
2021-11-09 Stock Options (Right to Buy) $1.48 M 1234 Disposed 2023-12-31 Common Stock (1234) Direct

Footnotes

F1: This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.

F2: This transaction was executed in multiple trades at prices ranging from $38.25 to $38.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $38.60 to $39.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.